Skip to main content

Table 2 Treatment-Related Outcomes at 12 Months by Treatment Status at Enrollment, REACH-OUT (2010–2013)

From: Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations

Variable PP-All N = 482 PP-C N = 308 PP-N N = 174 OAT (N = 281) P Value, PP-All vs OAT P Value, PP-N vs OAT
Discontinuation 62 (20%) 34 (17%) 28 (27%) 92 (51%) <0.001 <0.001
MPR (mean ± SD) 0.84 ± 0.20 0.85 ± 0.17 0.82 ± 0.23 0.52 ± 0.31 <0.001 <0.001
Nonadherence (MPR <80%) 118 (26%) 74 (25%) 44 (28%) 194 (75%) <0.001 <0.001
Adherence (MPR ≥80%) 332 (74%) 217 (75%) 115 (72%) 66 (25%)   
1-year PDC (Mean ± SD) 0.57 ± 0.39 0.60 ± 0.39 0.53 ± 0.39 0.31 ± 0.29 <0.001 <0.001
Nonadherence (PDC <80%) 270 (56%) 164 (53%) 106 (61%) 255 (91%) <0.001 <0.001
Adherence (PDC ≥80%) 212 (44%) 144 (47%) 68 (39%) 26 (9%)   
  1. Notes: (1) Percentages reported are among the nonmissing. Number missing discontinuation: PP-C, 33%; PP-N, 41%; OAT, 36%. Number missing MPR: PP-C, 6%; PP-N, 9%; OAT, 7%. Number missing PDC: PP-C, 0%; PP-N, 0%; OAT, 0%
  2. Abbreviations: MPR medication possession ratio, OAT oral antipsychotic therapy, PDC proportion of days covered, PP paliperidone palmitate, PP-C continuous user of paliperidone palmitate, PP-N new user of paliperidone palmitate, SD standard deviation